Insmed (INSM) Misses Q4 EPS by 30c
Get Alerts INSM Hot Sheet
Revenue Growth %: +20.6%
Financial Fact:
Operating loss: -37.15M
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Insmed (NASDAQ: INSM) reported Q4 EPS of ($1.00), $0.30 worse than the analyst estimate of ($0.70). Revenue for the quarter came in at $41.42 million versus the consensus estimate of $41.44 million.
"2020 was the most productive and significant year in Insmed's history, as we evolved from a single-product company with a successful U.S. launch to a truly global organization advancing three distinct, value-creating programs. I am incredibly proud of our team's performance, which is all the more exemplary against the backdrop of COVID-19," commented Will Lewis, Chair and Chief Executive Officer of Insmed. "In the fourth quarter, we initiated both the Phase 3 ASPEN study of brensocatib in patients with bronchiectasis and the ARIKAYCE frontline clinical trial program in patients with NTM lung disease caused by MAC; advanced our ARIKAYCE launch in Europe and prepared for a potential approval and launch in Japan while maintaining steady performance in the U.S.; and advanced the development of TPIP, for which we announced positive Phase 1 data just last week. We begin 2021 with incredible momentum and believe we have the capabilities and talent to achieve our ambitious vision."
For earnings history and earnings-related data on Insmed (INSM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
- UPS Q1 earnings top consensus expectations despite revenue dip
- LKQ Corporation (LKQ) Misses Q1 EPS by 13c, provides guidance
Create E-mail Alert Related Categories
Corporate News, Earnings, Management CommentsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!